Oasmia Pharmaceutical AB
OASM
OASM was delisted on the 21st of August, 2019.
4 hedge funds and large institutions have $253K invested in Oasmia Pharmaceutical AB in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
18% less capital invested
Capital invested by funds: $310K → $253K (-$57K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$17.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$68K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.81K |
OASM Hedge Fund Activity: Q3 2017 in Review
4 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Oasmia Pharmaceutical AB (OASM) for Q3 2017, worth a combined $253K — down 18% from $310K a quarter earlier.
Fund positioning in OASM was balanced in Q3 2017: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Old Mission Capital, opening a new position worth an estimated $17.5K. The largest seller was Jane Street, exiting entirely with an estimated $68K sold.
- 4 institutional investors held Oasmia Pharmaceutical AB (OASM) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $253K of Oasmia Pharmaceutical AB stock for Q3 2017, down 18% quarter-over-quarter.
- 1 fund opened new Oasmia Pharmaceutical AB positions in Q3 2017 and 1 closed out, a net change of 0 holders.
- The largest Oasmia Pharmaceutical AB buyer in Q3 2017 was Old Mission Capital, an estimated $17.5K added.
- The largest Oasmia Pharmaceutical AB seller in Q3 2017 was Jane Street, an estimated $68K sold.
Based on aggregated 13F filings for Q3 2017.